



The
Patent
Office

PO/EP 97 / 00994

09/14/2013
5

The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

PRIORITY DOCUMENT

REC'D	20 MAR 1997
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

19 February 1997

For Official use

- 2 MAR 1996

Your Reference: **JVB/KL/P31395**

9604518.2

Notes

Please type, or write in dark ink using CAPITAL letters. A prescribed fee is payable for a request for grant of a patent. For details, please contact the Patent Office (telephone 071-483 4700).

Rule 16 of the Patents Rules 1990 is the main rule governing the completion and filing of this form.

- ② Do not give trading styles, for example, 'Trading as XYZ company', nationality or former names, for example, 'formerly (known as) ABC Ltd' as these are not required.

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977 and will inform the applicant if such prohibition or restriction is necessary. Applicants resident in the United Kingdom are also reminded that under Section 23, applications may not be filed abroad without written permission unless an application has been filed not less than 6 weeks previously in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction revoked.

The Patent Office **Request for grant of a Patent**
Form 1/77 **Patents Act 1977**

① Title of invention

- 1 Please give the title of the invention **NOVEL COMPOUNDS**

② Applicant's details

☐ **First or only applicant**

- 2a If you are applying as a corporate body please give:
Corporate Name **SMITHKLINE BEECHAM PLC**

Country (and State of incorporation, if appropriate) **UNITED KINGDOM**

- 2b If you are applying as an individual or one of a partnership please give in full:

Surname

Forenames

2c In all cases, please give the following details:

Address: **NEW HORIZONS COURT
BRENTFORD
MIDDLESEX**

UK postcode **TW8 9EP**
(if applicable)

Country **ENGLAND**
ADP number
(if known)

536 07 74-2-3

2d, 2e and 2f: If there are further applicants please provide details on a separate sheet of paper

☐ **Second applicant (if any)**

2d If you are applying as a corporate body please give:
Corporate Name

Country (and State of
Incorporation, if appropriate)

2c If you are applying as an individual or one of a partnership please give in full:

Surname:

Forenames:

2f In all cases, please give the following details:

Address:

UK postcode
(if applicable)
Country
ADP number
(if known)

③ An address for service in the United Kingdom must be supplied

Please mark correct box.

③ **Address for service details**

3a Have you appointed an agent to deal with your application?

Yes ☒

No ☐ go to 3b



please give details below

Agent's name

Valentine J B

Agent's address:

CORPORATE INTELLECTUAL PROPERTY
SMITHKLINE BEECHAM PLC
SB HOUSE
GREAT WEST ROAD
BRENTFORD
MIDDLESEX

Postcode

TW8 9BD

Agent's ADP
number

4203417

3b: If you have appointed an agent, all correspondence concerning your application will be sent to the agent's United Kingdom address.

3b If you have not appointed an agent please give a name and address in the United Kingdom to which all correspondence will be sent:

Name:

Address

Postcode

Daytime telephone
number (if available)

ADP number
(if known)

JB V/KL/P31395

4. Agent's or applicant's reference number (if applicable)

⑤ Claiming an earlier application date

5. Are you claiming that this application be treated as having been filed on the date of filing of an earlier application?

Yes ☐

No ☒ ☐ go to 6



please give details below

☐ number of earlier application or patent number

☐ filing date (day month year)

☐ and the Section of the Patents Act 1977 under which you are claiming:

15(4) (Divisional) ☐8(3) ☐12(6) ☐

37(4) ☐

⑥ Declaration of priority

6. If you are declaring priority from previous application(s), please give:

Country of Filing

Priority application number
(if known)

Filing Date
(day, month, year)

Please mark correct box

Please mark correct box

⑥ If you are declaring priority from a PCT Application please enter 'PCT' as the country and enter the country code (for example, GB) as part of the application number

Please give the date in all number format, for example, 31/05/90 for 31 May 1990

7

- / applicant is not an inventor
- there is an inventor who is not
- an applicant, or
- any applicant is a corporate body.

8 Please supply duplicates of claim(s), abstract, description and drawings).

Please mark correct box(es)

9 You or your appointed agent (see Rule 90 of the Patents Rules 1990) must sign this request.

Please sign here →

A completed fee sheet should preferably accompany the fee.

7 Inventorship

7. Are you (the applicant or applicants) the sole inventor or the joint inventors?

Please mark correct box

Yes ☐

No ☒

A Statement of Inventorship on Patents form 7/77 will need to be filed (see Rule 15).).

8 Checklist

8a Please fill in the number of sheets for each of the following types of document contained in this application

Continuation sheets for this Patents Form 1/77

Claim(s) -

Description 20

Abstract -

Drawing(s) -

8b Which of the following documents also accompanies the application?

Priority documents (please state how many)

Translation(s) of Priority documents (please state how many)

Patents Form 7/77 - Statement of Inventorship and Right to Grant

Patents Form 9/77 - Preliminary Examination Report

Patents Form 10/77 - Request for Substantive Examination

9 Request

I/We request the grant of a patent on the basis of this application.

Signed

J B Valentine

Date: 1st March 1996

J B Valentine

(day month year)

Please return the completed form, attachments and duplicates where requested, together with the prescribed fee to either;

☐ The Comptroller
The Patent Office
Cardiff Road
Newport
Gwent
NP9 1RH

or

☐ The Comptroller
The Patent Office
25 Southampton Buildings
London
WC2A 1AY

NOVEL COMPOUNDS

The present invention relates to polypeptides and their use in the diagnosis and therapy of disorders involving complement activity and various inflammatory and immune disorders.

Constituting about 10% of the globulins in normal serum, the complement system is composed of many different proteins that are important in the immune system's response to foreign antigens. The complement system becomes activated when its primary components are cleaved and the products alone or with other proteins, activate additional complement proteins resulting in a proteolytic cascade. Activation of the complement system leads to a variety of responses including increased vascular permeability, chemotaxis of phagocytic cells, activation of inflammatory cells, opsonization of foreign particles, direct killing of cells and tissue damage. Activation of the complement system may be triggered by antigen-antibody complexes (the classical pathway) or, for example, by lipopolysaccharides present in cell walls of pathogenic bacteria (the alternative pathway).

Complement activation (CA) is known to occur in a wide variety of acute inflammatory processes particularly those associated with ischaemia and reperfusion injury (Rossen et al., 1985 Circ. Res., 57, 119.; Morgan B.P., 1990 The biological effects of complement activation. In '*Complement, Clinical Aspects and Relevance to Disease*'. Academic Press. London.)

It is generally accepted that at least some of the components of the classical complement cascade can be detected by immunohistochemical methods in close association with senile plaques in AD brain (Eikelenboom et al., 1994, Neuroscience, 59, 561-568). There is good evidence for the involvement of C1, C3 and C4, but evidence for the presence of the C5-C9 membrane-attack complex (MAC) is not yet evident (Veerhuis et al, 1995, Vichows Arch. 426, 603-610). Cells of the CNS have been shown to synthesise complement components (for review see Barnum, 1995 Crit. Rev. Oral. Biol. Med 6, 132-146), and production of C3 is enhanced in response to incubation with bA4 peptide (Haga et al., 1993 Brain Res., 601, 88-94). Thus complement can be induced locally in the brain itself and is not necessarily derived solely from the plasma compartment.

Of particular interest is the fact that the bA4 peptide has been found to bind directly to the initial component of the complement cascade (C1q) and to initiate the whole of the classical complement system *in vitro* (including MAC) by an antibody-independent mechanism (Rogers et al., 1992, Proc. Nat. Acad. Sci. USA., 89, 10016-10020.; Jianh et al., 1994, J. Immunol., 152, 5050-5059). This interaction appears to involve region 6-16 of β A4 and 14-26 of the collagen-like tail region of the C1q A

chain. The latter site is separate from the IgG-immune complex binding site located on the globular head domain of C1q. There is some evidence that fibrillar bA4 binds with higher affinity to C1q than monomeric peptide, potentially providing a rational basis for activation of complement in the disease process (Jiang et al., 1994, J.

5 Immunol., 152, 5050-5059; Snyder et al., 1994, Exp. Neurol., 128, 136-142).

Complement receptor type 1 (CR1) has been shown to be present on the membranes of erythrocytes, monocytes/macrophages, granulocytes, B cells, some T cells, splenic follicular dendritic cells, and glomerular podocytes. CR1 binds to the complement components C3b and C4b and has also been referred to as the C3b/C4b
10 receptor. The structural organisation and primary sequence of one allotype of CR1 is known (Klickstein *et al.*, 1987, J. Exp. Med. 165:1095-1112, Klickstein *et al.*, 1988, J. Exp. Med. 168:1699-1717; Hourcade *et al.*, 1988, J. Exp. Med. 168:1255-1270, WO 89/09220, WO 91/05047). It is composed of 30 short consensus repeats (SCRs) that each contain around 60-70 amino acids. In each SCR, around 29 of the average
15 65 amino acids are conserved. Each SCR has been proposed to form a three dimensional triple loop structure through disulphide linkages with the third and first and the fourth and second half-cystines in disulphide bonds. CR1 is further arranged as 4 long homologous repeats (LHRs) of 7 SCRs each. Following a leader sequence, the CR1 molecule consists of the N-terminal LHR-A, the next two repeats, LHR-B
20 and LHR-C, and the most C-terminal LHR-D followed by 2 additional SCRs, a 25 residue putative transmembrane region and a 43 residue cytoplasmic tail.

Based on the mature CR1 molecule having a predicted N-terminal glutamine residue, hereinafter designated as residue 1, the first four SCR domains of LHR-A are defined herein as consisting of residues 2-58, 63-120, 125-191 and 197-252,
25 respectively, of mature CR1.

Hourcade *et al.*, 1988, J. Exp. Med. 168:1255-1270 observed an alternative polyadenylation site in the human CR1 transcriptional unit that was predicted to produce a secreted form of CR1. The mRNA encoded by this truncated sequence comprises the first 8.5 SCRs of CR1, and encodes a protein of about 80 kDa which
30 was proposed to include the C4b binding domain. When a cDNA corresponding to this truncated sequence was transfected into COS cells and expressed, it demonstrated the expected C4b binding activity but did not bind to C3b (Krych *et al.*, 1989, FASEB J. 3:A368; Krych *et al.* Proc. Nat. Acad. Sci. 1991, 88, 4353-7). Krych *et al.*, also observed a mRNA similar to the predicted one in several human cell lines and
35 postulated that such a truncated soluble form of CR1 with C4b binding activity may be synthesised in humans.

In addition, Makrides *et al.* (1992, J. Biol. Chem. 267 (34) 24754-61) have expressed SCR 1 + 2 and 1 + 2 + 3 + 4 of LHR-A as membrane-attached proteins in CHO cells.

Several soluble fragments of CR1 have also been generated via recombinant DNA procedures by eliminating the transmembrane region from the DNAs being expressed (WO 89/09220, WO 91/05047). The soluble CR1 fragments were functionally active, bound C3b and/or C4b and demonstrated Factor I cofactor activity depending upon the regions they contained. Such constructs inhibited *in vitro* complement-related functions such as neutrophil oxidative burst, complement mediated hemolysis, and C3a and C5a production. A particular soluble construct, sCR1/pBSCR1c, also demonstrated *in vivo* activity in a reversed passive Arthus reaction (WO 89/09220, WO 91/05047; Yeh *et al.*, 1991, J. Immunol. 146:250), suppressed post-ischemic myocardial inflammation and necrosis (WO 89/09220, WO 91/05047; Weisman *et al.*, Science, 1990, 249:146-151; Dupe, R. *et al.* Thrombosis & Haemostasis (1991) 65(6) 695.) and extended survival rates following transplantation (Pruitt & Bollinger, 1991, J. Surg. Res 50:350; Pruitt *et al.*, 1991 Transplantation 52; 868). Furthermore, co-formulation of sCR1/pBSCR1c with p-anisoylated human plasminogen-streptokinase-activator complex (APSAC) resulted in similar anti-haemolytic activity as sCR1 alone, indicating that the combination of the complement inhibitor sCR1 with a thrombolytic agent was feasible (WO 91/05047).

In a model of antibody-mediated demyelinating experimental allergic encephalomyelitis (ADEAE), systemic inhibition of CA using sCR1 over 6 days, produced improvements in clinical score and blocked CNS inflammation, demyelination and deposition of complement components (Piddlesden *et al.*, 1994, J. Immunol. 152, 5477). ADEAE can be regarded as a model of acute relapse in multiple sclerosis (MS) and these striking results suggested possible applications for sCR1 in MS therapy despite the high molecular weight (245 kilodaltons) of this agent.

In a rat model of traumatic brain injury, complement inhibitor sCR1 (BRL55730) was shown to reduce myeloperoxidase activity (an indicator of neutrophil accumulation) following traumatic injury (Kaczorowska *et al.*, 1995, J. Cerebral Blood Flow and Metabolism, 15, 860-864). This is suggested as demonstrating that complement activation is involved in the local inflammatory response.

Soluble polypeptides corresponding to part of CR1 having functional complement inhibitory, including anti-haemolytic, activity have been described in WO94/00571 comprising, in sequence, one to four short consensus repeats (SCR)

selected from SCR 1, 2, 3 and 4 of long homologous repeat A (LHR-A) s the only structurally and functionally intact SCR domains of CR1 and including at least SCR3.

According to the present invention there is provided a polypeptide derived from a sequence of the general formula (I):

5 CNPGSGGRKVFELVGEPsiYCTSNDDQVGIWSG (1)

of 6 to 23 amino acids in length and comprising sequence a) and/or b):

a) GGRKVF

b) FELVGEPsiY

10 The peptides of the invention are derived from the region of SCR3 of human CR1 between amino acids C154 to G186.

It is to be understood that variations in the amino acid sequence of the polypeptide of the invention by way of addition, deletion or conservative substitution of residues, including allelic variations, in which the biological activity of the polypeptide is retained, are encompassed by the invention. Conservative substitution
15 is understood to mean the retention of the charge and size characteristics of the amino acid side chain, for example arginine replaced by histidine.

The polypeptide may be modified to have cysteine residues at the C and N termini to provide a cyclic molecule bridged by a disulphide bond. The peptide may also be altered at specific amino acids to remove chemically reactive amino acids.

20 The polypeptide may have chemically reactive amino acids such as cysteine, lysine or glutamic acid at the N or C-terminal ends optionally further derivatised or derivatisable to provide a route for chemical linkage to other peptides or chemicals. Preferably, the terminal amino acid is cysteine and a derivative is S- (2-pyridyl) dithio.

25 Enhanced activity may be achieved by forming multimerised polypeptides. According to the present invention there is provided a multimeric polypeptide comprising two or more, for example two to eight, polypeptides of the invention, linked to a core peptide or multifunctional molecule. The core peptide is preferably a lysine derivative such as the 'MAP' peptide (Posnett, D.N. & Tam, J.P, Methods in
30 Enzymology, 1989, 178, 739-746) exemplified by (lys)₄(lys)₂ lys ala in which the first lysine has two further lysines linked to both alpha and epsilon amino groups and the second two lysines each have two further lysines thus giving a branched (dendritic) polymer with eight unsubstituted amino groups. Other examples of core structures include Tris (aminoethyl) amine and 1,2,4,5 benzene tetracarboxylic acid.
35 Each polypeptide is linked to the core structure. Preferably, a cysteine-terminated peptide is linked to thiol-reactive core structure.

In a further aspect, the invention provides chimaeric polypeptides in which a polypeptide of formula (I) is inserted in or substituted for sequences not essential to the overall architecture or folding pathway of a host protein.

In one alternative the host protein contains one or more SCR repeat, such as an
5 SCR-containing protein of the complement control protein family, for example factor H, C4 binding protein, decay accelerating factor, membrane cofactor protein or complement receptor 2. Such insertions or additions are used as a means of adding and/or enhancing anti-complement activity of the host protein. Preferably such substitutions or insertions are made into loop regions (predicted from secondary
10 structure prediction algorithms, homology modelling of tertiary structure or by sequence alignments which identify variable-length insertions in an otherwise conserved sequence background) of the SCR-type module.

In another alternative the host protein is a plasma protein and the insertion or substitution is used to alter the stability of the polypeptide *in vivo*. Suitable examples
15 of such substitutions or insertions include those into a surface loop of an immunoglobulin Fc domain, a non-complementarity-determining region (CDR) of an Fab domain, a turn region of a kringle or growth factor domain or a beta-turn in a 'finger' domain such as those found in fibronectin.

The term polypeptide will be used hereafter to refer to polypeptides derived
20 from the sequence of general formula (I) as well as multimerised polypeptides and chimeric polypeptides of the invention.

In a further aspect, the invention provides a process for preparing a polypeptide according to the invention which process comprises expressing DNA encoding said polypeptide in a recombinant host cell and recovering the product.

25 In particular, the process may comprise the steps of:

- i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said polypeptide;
- ii) transforming a host cell with said vector;
- iii) culturing said transformed host cell under conditions permitting expression of
30 said DNA polymer to produce said polypeptide; and
- iv) recovering said polypeptide.

The DNA polymer comprising a nucleotide sequence that encodes the polypeptide also forms part of the invention.

The process of the invention may be performed by conventional recombinant
35 techniques such as described in Sambrook *et al.*, Molecular Cloning : A laboratory manual 2nd Edition. Cold Spring Harbor Laboratory Press (1989) and DNA Cloning vols I, II and III (D. M. Glover ed., IRL Press Ltd).

The invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.

The preparation may be carried out chemically, enzymatically, or by a combination of the two methods, *in vitro* or *in vivo* as appropriate. Thus, the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Roberts *et al.*, in Biochemistry 1985, 24, 5090-5098.

The DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation, or by a combination of these methods.

Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50µl or less with 0.1-10µg DNA.

Enzymatic polymerisation of DNA may be carried out *in vitro* using a DNA polymerase such as DNA polymerase 1 (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50µl or less.

Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to 37°C, generally in a volume of 50µl or less.

The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes M. Singh, B.S. Sproat and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S.P. Adams *et al.*, Journal of the American Chemical Society, 1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes *et al.*, EMBO Journal, 1984, 3, 801. Preferably an automated DNA synthesiser (for example, Applied Biosystems 381A Synthesiser) is employed.

The DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the polypeptide.

The DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences.

The precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product. The design of a suitable strategy for the construction of the DNA molecule coding for the polypeptide is a routine matter for the skilled worker in the art.

5 In particular, consideration may be given to the codon usage of the particular host cell. The codons may be optimised for high level expression in *E. coli* using the principles set out in Devereux *et al.*, (1984) Nucl. Acid Res., **12**, 387.

The expression of the DNA polymer encoding the polypeptide in a recombinant host cell may be carried out by means of a replicable expression vector
10 capable, in the host cell, of expressing the DNA polymer. The expression vector is novel and also forms part of the invention.

The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or
15 more DNA molecules which, together with said linear segment, encode the polypeptide, under ligating conditions.

The ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.

Thus, the DNA polymer may be preformed or formed during the construction
20 of the vector, as desired. The choice of vector will be determined in part by the host cell, which may be prokaryotic, such as *E. coli*, or eukaryotic, such as mouse C127, mouse myeloma, chinese hamster ovary, fungi e.g. filamentous fungi or unicellular 'yeast' or an insect cell such as *Drosophila*. The host cell may also be in a transgenic animal. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant
25 viruses derived from, for example, baculoviruses or vaccinia.

The DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the fragment e.g. bovine papillomavirus vectors in mouse C127 cells, or amplified vectors in chinese hamster ovary cells (DNA Cloning Vol. II D.M. Glover ed. IRL Press 1985; Kaufman, R.J. *et al.*. Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H. Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, D.V. *et al.*, European Patent Application No. 0093619, 1983).
30

The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation
35 of the DNA, by procedures described in, for example, Sambrook *et al.*, cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an

appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50µl or l with 0.1-10µg DNA.

The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Sambrook *et al.*, cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.

The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as *E.coli*, may be treated with a solution of CaCl₂ (Cohen *et al.*, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl₂, potassium acetate and glycerol, and then with 3-[N-morpholino]-propane-sulphonic acid, RbCl and glycerol or by electroporation as for example described by Bio-Rad Laboratories, Richmond, California, USA, manufacturers of an electroporator. Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells or by using cationic liposomes.

The invention also extends to a host cell transformed with a replicable expression vector of the invention.

Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Sambrook *et al.*, and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C.

The protein product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial such as *E. coli* and the protein is expressed intracellularly, it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is mammalian, the product is usually isolated from the nutrient medium.

Where the host cell is bacterial, such as *E. coli*, the product obtained from the culture may require folding for optimum functional activity. This is most likely if the protein is expressed as inclusion bodies. There are a number of aspects of the isolation and folding process that are regarded as important. In particular, the polypeptide is preferably partially purified before folding, in order to minimise formation of aggregates with contaminating proteins and minimise misfolding of the polypeptide. Thus, the removal of contaminating *E. coli* proteins by specifically isolating the inclusion bodies and the subsequent additional purification prior to folding are important aspects of the procedure.

The folding process is carried out in such a way as to minimise aggregation of intermediate-folded states of the polypeptide. Thus, careful consideration needs to be given to, among others, the salt type and concentration, temperature, protein

concentration, redox buffer concentrations and duration of folding. The exact condition for any given polypeptide generally cannot be predicted and must be determined by experiment.

There are numerous methods available for the folding of proteins from inclusion bodies and these are known to the skilled worker in this field. The methods generally involve breaking all the disulphide bonds in the inclusion body, for example with 50mM 2-mercaptoethanol, in the presence of a high concentration of denaturant such as 8M urea or 6M guanidine hydrochloride. The next step is to remove these agents to allow folding of the proteins to occur. Formation of the disulphide bridges requires an oxidising environment and this may be provided in a number of ways, for example by air, or by incorporating a suitable redox system, for example a mixture of reduced and oxidised glutathione.

Preferably, the inclusion body is solubilised using 8M urea, in the presence of mercaptoethanol, and protein is folded, after initial removal of contaminating proteins, by addition of cold buffer. A preferred buffer is 20mM ethanolamine containing 1mM reduced glutathione and 0.5mM oxidised glutathione. The folding is preferably carried out at a temperature in the range 1 to 5°C over a period of 1 to 4 days.

If any precipitation or aggregation is observed, the aggregated protein can be removed in a number of ways, for example by centrifugation or by treatment with precipitants such as ammonium sulphate. Where either of these procedures are adopted, monomeric polypeptide is the major soluble product.

If the bacterial cell secretes the protein, folding is not usually necessary.

Alternatively the polypeptide may be synthesised by conventional solid phase peptide synthesis, for example using an automated peptide synthesiser and Fmoc (9-fluorenylmethoxycarbonyl) chemistry on *para*-alkoxybenzyl alcohol (Wang) resin with the C-terminal amino acid pre-attached.

Accordingly, in a further aspect the invention provides a process for preparing a polypeptide of the invention which comprises condensing appropriate peptide units.

The polypeptide of this invention is useful in the treatment or diagnosis of many complement-mediated or complement-related diseases and disorders including, but not limited to, those listed below.

Disease and Disorders Involving Complement

Neurological Disorders

multiple sclerosis

stroke

Guillain Barré Syndrome

traumatic brain injury
Parkinson's disease
allergic encephalitis
Alzheimer's disease

5

Disorders of Inappropriate or Undesirable Complement Activation

haemodialysis complications
hyperacute allograft rejection
xenograft rejection

10

corneal graft rejection
interleukin-2 induced toxicity during IL-2 therapy
paroxysmal nocturnal haemoglobinuria

Inflammatory Disorders

15

inflammation of autoimmune diseases
Crohn's Disease
adult respiratory distress syndrome
thermal injury including burns or frostbite
uveitis

20

psoriasis
asthma
acute pancreatitis

Post-Ischemic Reperfusion Conditions

25

myocardial infarction
balloon angioplasty
atherosclerosis (cholesterol-induced) & restenosis
hypertension
post-pump syndrome in cardiopulmonary bypass or renal haemodialysis
30 renal ischemia
intestinal ischaemia

Infectious Diseases or Sepsis

35

multiple organ failure
septic shock

Immune Complex Disorders and Autoimmune Diseases

rheumatoid arthritis

systemic lupus erythematosus (SLE)

SLE nephritis

proliferative nephritis

glomerulonephritis

5 haemolytic anemia

myasthenia gravis

Reproductive Disorders

antibody- or complement-mediated infertility

10

Wound Healing and Prevention of Scar Formation

The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide, as above, and a pharmaceutically acceptable carrier or excipient.

15

The present invention also provides a method of treating a disease or disorder associated with inflammation or inappropriate complement activation comprising administering to a subject in need of such treatment a therapeutically effective amount of a polypeptide of this invention.

20

The invention additionally provides the use of a polypeptide of the invention for the preparation of a medicament for the treatment of a disease or disorder associated with inflammation or inappropriate complement activation.

In the above methods, the subject is preferably a human.

An effective amount of the polypeptide for the treatment of a disease or disorder is in the dose range of 0.01-100mg/kg; preferably 0.1mg-10mg/kg.

25

For administration, the polypeptide should be formulated into an appropriate pharmaceutical or therapeutic composition. Such a composition typically contains a therapeutically active amount of the polypeptide and a pharmaceutically acceptable excipient or carrier such as saline, buffered saline, dextrose, or water. Compositions may also comprise specific stabilising agents such as sugars, including mannose and mannitol, and local anaesthetics for injectable compositions, including, for example, lidocaine.

30

Further provided is the use of a polypeptide of this invention in the manufacture of a medicament for the treatment of a disease or disorder associated with inflammation or inappropriate complement activation.

35

The present invention also provides a method for treating a thrombotic condition, in particular acute myocardial infarction, in a human or non-human animal. This method comprises administering to a human or animal in need of this treatment

an effective amount of a polypeptide according to this invention and an effective amount of a thrombolytic agent. Such methods and uses may be carried out as described in WO 91/05047.

5 This invention further provides a method for treating adult respiratory distress syndrome (ARDS) in a human or non-human animal, comprising administering to the patient an effective amount of a polypeptide according to this invention.

The invention also provides a method of delaying hyperacute allograft or hyperacute xenograft rejection in a human or non-human animal which receives a transplant by administering an effective amount of a polypeptide according to this
10 invention. Such administration may be to the patient or by application to the transplant prior to implantation.

The invention yet further provides a method of treating wounds in a human or non-human animal by administering by either topical or parenteral e.g. intravenous routes, an effective amount of a polypeptide according to this invention.

15 The invention still further provides a method of treating Alzheimer's Disease by administering to the patient an effective amount of a polypeptide according to this invention.

This invention also provides a method of treating CNS inflammatory disorders such as those associated with ischaemic stroke by administering to the patient an
20 effective amount of a polypeptide according to this invention.

METHODS

SDS Polyacrylamide gel electrophoresis

25 Novex precast gels 4-20% were purchased from British Biotechnology and used in Xcell II electrophoresis cells according to the manufacturers instructions.

Peptide Synthesis

30 Peptides were synthesised by the solid phase technique using an Applied Biosystems 430A peptide synthesiser and Fmoc (9-fluorenylmethoxycarbonyl) chemistry on *para*-alkoxybenzyl alcohol (Wang) resin with the C-terminal amino acid pre-attached. The resin was treated with benzoic anhydride (2 mmol) in the presence of N,N - dicyclohexylcarbodiimide (1 mmol) and 4-dimethylaminopyridine (0.04 mmol) in N-methylpyrrolidone (NMP) and N,N-dimethylformamide (DMF) in
35 order to block any residual free hydroxy groups prior to chain elongation. Each single-coupling cycle consisted of the following steps: 1. The resin was washed with NMP (x1); 2. Fmoc deprotection was carried out with two consecutive treatments (3 min and 15 min) of the resin using a solution of piperidine in NMP (starting concentration 20% v/v); 3. The resin was washed with NMP (x5); 4. The resin was

- coupled (60 min) with a solution of the preactivated amino acid (1 mmol) in NMP and DMF; 5. The resin was washed with NMP (x7). In the case of a double-coupling cycle, steps 4 and 5 were conducted twice. Fmoc amino acids (1 mmol) were pre-activated with 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium
- 5 hexafluorophosphate (HBTU) (1 mmol) in the presence of 1-hydroxybenzotriazole (HOBt) (1 mmol) and N,N-diisopropylethylamine (DIEA) (2 mmol) for 6 to 12 min. After chain elongation, the Fmoc group was removed. The side chain protection used was 2,2,5,7,8-pentamethylchroman-6-sulphonyl (Pmc) for arginine, trityl for asparagine, glutamine and cysteine, *tert*-butyloxycarbonyl for lysine and tryptophan,
- 10 and *tert*-butyl for serine, threonine, aspartic acid and glutamic acid. All residues were double-coupled unless stated.

Cleavage from the resin

- The ice-cooled peptidyl resin was treated with ice-cooled cleavage mixture A or B (10 ml) and stirred for 2 h at room temperature. The mixture was filtered and
- 15 the filtrate evaporated *in vacuo* to a low volume (3 to 5 ml) of solution. This was azeotroped *in vacuo* with dry toluene (x 2) and the residual oil triturated with dry diethyl ether (3 x 50 ml) to give a white precipitate. This was collected and dried *in vacuo* to remove any trace of diethyl ether prior to lyophilisation from dilute aqueous
- 20 acetic acid. The cleavage mixtures used were A: TFA/water/thioanisole/1,2-ethanedithiol (EDT)/phenol (88.9 : 4.4 : 4.4 : 2.2 : 6.7 v/v/v/v/w); B: TFA/water/EDT (75 : 5 : 20 v/v/v).

High Performance Liquid Chromatography (HPLC)

- 25 Separations were carried out using a Gilson gradient system with detection at 220 nm. Analytical HPLC was conducted on a Spherisorb C-18 column (25 cm x 4.6 mm id) eluted at 1 ml/min and preparative HPLC was conducted on a Spherisorb C-8 column (25 cm x 10 mm id) eluted at 4 ml/min unless stated, with eluents A = 0.1 % aqueous TFA and B = acetonitrile. Gradients used were A: isocratic elution for
- 30 5 min at 10% B followed by a 45 min linear gradient to 60% B; B: isocratic elution for 5 min at 10% B followed by a 45 min linear gradeint to 80% B; C: isocratic elution for 5 min at 10% B followed by a 50 min linear gradient to 50% B; D: isocratic elution for 1 min at 10% B followed by a 30 min linear gradient to 80% B;
- 35 B: isocratic elution for 5 min at 15% B followed by a 60 min linear gradient to 30% B; F: isocratic elution for 1 min at 30% B followed by a 30 min linear gradient to 40% B; G: isocratic elution for 5 min at 10% B followed by a 60 min linear gradient to 40% B; H: isocratic elution for 5 min at 1% B followed by a 60 min linear gradient to 35% B; I: isocratic elution for 5 min at 5% B followed by a 60 min linear gradient

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

(column 83 cm x 2.5 cm id; detection at 220 nm) using 1M aqueous acetic acid as eluent. The peptide eluted as a single peak which was split into six fractions (combined weight 0.082 g; 49 %): A (11 mg), B (22 mg), C (17 mg), D (24 mg), E (4 mg) and F (4 mg).

5

1b Characterisation of E1

HPLC analysis using gradient F showed the presence of three peaks of retention times 17.8 min (peak 1), 18.6 min (peak 2) and 19.8 min (peak 3) in each fraction in proportions as shown:-

10

Fraction	Peak 1	Peak 2	Peak 3	Earlier-eluting material
A	6	15	61	18
B	15	11	61	13
C	36	14	50	-
15 D	49	16	35	-
E	72	20	8	-
F	54	14	6	26

Peaks 1 and 3 were shown to be a reduced and oxidised form of the peptide respectively by treatment with dithiothreitol (DTT) and with dimethylsulphoxide (DMSO). Peak 2 was an unknown contaminant which was not affected by DTT nor DMSO. An aqueous solution of fraction B (pH 7.5) was treated with excess DTT; HPLC after 6 h using gradient F showed peak 1 increased whilst peak 3 decreased. Fraction B was treated with an aqueous solution of DMSO (20% v/v); HPLC using gradient F after 11 h showed the disappearance of peak 1 whilst peak 3 increased. An aqueous solution of fraction E (pH 7.5) was treated with excess DTT; HPLC after 5.8 h using gradient F showed the disappearance of peak 3 whilst peak 1 increased. Fraction E was treated with an aqueous solution of DMSO (20% v/v); HPLC using gradient F after 12 h showed the disappearance of peak 1 whilst peak 3 increased.

Electrospray mass spectrometry gave evidence that peaks 1 and 3 were the linear (E1a) and cyclic (E1b) forms of the peptide respectively.

Fraction A gave ions corresponding to $[M+2H]^{2+}$ at m/z 1105.8 (rel. intensity 53%, deconvoluted corresponds to mw 2209.6, calculated for cyclic form 2209.0), m/z 1106.3 (66%, 2210.6), and m/z 1106.8 (53%, 2211.6, calculated for linear form 2210.0).

Fraction C gave ions corresponding to $[M+2H]^{2+}$ at m/z 1105.8 (41%, 2209.6), m/z 1106.4 (66%, 2210.8), m/z 1106.9 (100%, 2211.8), m/z 1107.3 (98%, 2212.6), and m/z 1107.8 (75%, 2213.6).

Fraction F gave ions corresponding to $[M+2H]^{2+}$ at m/z 1106.8 (98%, 2210.6), m/z 1107.3 (99%, 2212.6) and m/z 1107.7 (83%, 2213.4).

Amino acid analysis: Fraction A: Asx 1.0 (theoretical 1), Glu 2.4 (2), Ser 2.3 (2), Gly 4.2 (4), Arg 1.3 (1), Pro 2.2 (2), Tyr 0.9 (1), Val 1.5 (2), Cys 1.1 (2), Ile 1.1 (1), Leu 1.3 (1), Phe 0.1 (1), Lys 1.7 (1). Fraction C: Asx 1.1, Glu 2.5, Ser 2.1, Gly 4.0, Arg 1.2, Pro 2.1, Tyr 1.0, Val 1.6, Cys 1.1, Ile 1.1, Leu 1.3, Phe 0.1, Lys 1.8. Fraction F: Asx 1.1, Glu 2.4, Ser 2.3, Gly 4.1, Arg 1.2, Pro 2.4, Tyr 1.1, Val 1.4, Cys 0.9, Ile 1.3, Leu 1.1, Phe 0.1, Lys 1.6. (Note: Cys partially destroyed and Val-Phe bond only partially hydrolysed on acid hydrolysis.)

EXAMPLE 2: S158-C174 (E2)

SGGRKVFELVGEPsiYC (E2)

This peptide spans the sequence from mature human CR1 S158 to C174.

2a Synthesis of E2

Stepwise assembly from Fmoc-Cys(Trt)-resin (0.49 g; 0.25 mmol) gave the 17-residue peptidyl resin with the N-terminal Fmoc group removed (1.03 g). Residues Ser¹, Gly^{2,11}, Phe⁷, Glu^{8,12} and Pro¹³ were single-coupled. The peptidyl resin (0.51 g) was cleaved using mixture A to give crude solid (0.22 g) after lyophilisation. Purification of 0.072 g by preparative HPLC using gradients A, B and C gave purified solid (0.048 g; 66%).

2b Characterisation of E2

The product was >95% pure by analytical HPLC and had a retention time of 18.6 min using gradient D. Its identity was verified by observation of a $[M+H]^+$ ion in the FAB mass spectrum at m/z 1842 and by an amino acid analysis of Glx 1.97 (theoretical 2), Ser 1.86 (2), Gly 2.85 (3), Arg 1.13 (1), Pro 1.08 (1), Tyr 0.94 (1), Val 1.82 (2), Ile 0.99 (1), Leu 1.12 (1), Phe 1.11 (1), Lys 1.14 (1). (Cys not calculated due to its destruction on acid hydrolysis.)

EXAMPLE 3: Multiple Antigen Peptide (MAP)-E2 conjugate (E3)

To potentiate the activity of SCRPEP2, multiple binding sites were created by crosslinking SCRPEP2 to a lysine core residue.

3a Derivatisation of MAP peptide.

(i) N-(2-Pyridyl)dithiopropionyl MAP

MAP peptide (structure (Lys)₄ (Lys)₂ Ala -OH) was purchased from Peptide and Protein Research, Exeter, UK. Peptide (9.8 mg, 10 micromoles) was dissolved in a mixture of dry dimethylsulphoxide (DMSO, 100 microlitres) and dry ACS-grade pyridine (200 microlitres) in which had been dissolved 3-(2-pyridyl)dithiopropionic acid N-oxy succinimide ester (Pharmacia, 25mg, 80 micromoles, 1 mol equivalent to free amino groups in the MAP peptide). The clear solution was agitated gently overnight (15h) at ambient temperature (~22°C) and then stored at -80°C.

3a.2 Conjugation to SCRPEP2. Peptide 2 (as above, 7.4mg, 4 micromoles) was dissolved in a mixture of dry DMSO (180 microlitres) and dry ACS-grade pyridine (90 microlitres) and the above PDP-MAP (15 microlitres of solution, ~0.5 micromoles, ~4 micromoles PDP-equivalent) added. The mixture was agitated under dry nitrogen for 6h at ambient temperature and a slight yellow colour was noted. It was then diluted to a final volume of 1.5ml with 20mM Ammonium Bicarbonate pH 7.4 at 4°C. The slightly cloudy solution was applied to a 1 x 10cm column of Sephadex G-25m equilibrated and eluted with the ammonium bicarbonate buffer at 4°C. Fractions eluting between 2.5 and 5.5 ml, 5.5 and 7.5ml and 7.5 and 9.0 ml were collected and lyophilised. Only the first of these contained measurable solid as a white powder (approx 14 mg).

20 3b Characterisation of Map-E2 conjugate

The elution position of the conjugate on the Sephadex G-25 column suggested an effective molecular weight of ~10,000. This corresponds to a minimum of 4 E2 units disulphide-linked to the MAP (theoretical M_r 9910). The maximum substitution is 8 units/MAP (theoretical M_r 17,750).

25 EXAMPLE 4: C-(G159-F164)-C (E4)

CGGRKVFEC (E4)

30 This sequence spans residues of G159 - F164 of mature human CR1. To enable circulisation cysteine has been added to the N and C-terminal ends of the peptide.

35 4a Synthesis of E4

Stepwise assembly from Fmoc-Cys(Trt)-resin (0.49 g; 0.25 mmol) gave the 8-residue peptidyl resin with the N-terminal Fmoc group removed (0.74 g). Residues Gly^{2,3} were single-coupled. The peptidyl resin (0.68 g) was cleaved using mixture

A to give crude solid (0.22 g) after lyophilisation. Purification by preparative HPL using gradients G, H and I gave purified solid (0.017 g; 8.6%).

4b Characterisation of E4

5 The product was >90% pure by analytical HPLC and had a retention time of 14.6 min using gradient J. The product was shown to be in an oxidised form by treatment with DTT and with DMSO. An aqueous solution of the product (pH 7.5) was treated with excess DTT; HPLC after 2.3 h using gradient J showed the peak at RT 14.6 min decreased whilst a new peak at RT 15.0 min appeared. The product was
10 treated with an aqueous solution of DMSO (20% v/v); HPLC using gradient J after 1.3 h showed no change. Its identity as the cyclic peptide was verified by observation of a $[M+H]^+$ ion in the FAB mass spectrum at m/z 868.

EXAMPLE 5: F164-G186 (C174S) (E5)

15

N-terminal end FELVGEPSTYSTSNDDQVGIWSG C-terminal end

This peptide spans the residues F164 - G186 of mature human CR1. C174 has been substituted with serine.

20

5a Synthesis of E5

Stepwise assembly from Fmoc-Gly-resin (0.14 g; 0.10 mmol) gave the 23-residue peptidyl resin with the N-terminal Fmoc group removed (0.51 g). Residues Phe¹, Glu², Gly⁵, Pro⁷, Tyr¹⁰, Ser^{13,22}, Asn¹⁴ and Asp^{15,16} were single-coupled.
25 The peptidyl resin (0.24 g) was cleaved using mixture B to give crude solid (0.14 g) after lyophilisation. Purification by preparative HPLC on a Spherisorb C-18 column (25 cm x 4.6 mm id) using gradient E gave purified solid (0.0039 g; 3.3%).

5b Characterisation of E5

30 The product was >90% pure by analytical HPLC and had a retention time of 12.2 min using gradient F. Its identity was verified by observation of a $[M+H]^+$ ion in the FAB mass spectrum at m/z 2501 and by an amino acid analysis of Asx 2.91 (theoretical 3), Glx 3.01 (3), Ser 3.99 (4), Gly 2.88 (3), Thr 1.07 (1), Pro 1.05 (1), Tyr 0.87 (1), Val 2.47 (2), Ile 1.75 (2), Leu 0.97 (1), Phe 1.00 (1). (Trp not calculated
35 due to its destruction on acid hydrolysis.)

BIOLOGICAL ACTIVITY

Anti-Complement Activity Measured By the Haemolysis of Sheep Erythrocytes

Functional activity of complement inhibitors was assessed by measuring the inhibition of complement mediated lysis of sheep erythrocytes sensitised with rabbit antibodies (obtained from Diamedix Corporation, Miami, USA). Human serum diluted 1/125 in 0.1 M Hepes pH 7.4/ 0.15 M NaCl buffer was the source of
 5 complement and was prepared from a pool of volunteers essentially as described in (Dacie & Lewis, 1975). Briefly, blood was warmed to 37°C for 5 minutes, the clot removed and the remaining serum clarified by centrifugation. The serum fraction was split into small aliquots and stored at -196°C. Aliquots were thawed as required and diluted in the Hepes buffer immediately before use. Where indicated, nitrogen
 10 gas or helium gas were bubbled through the buffer for approximately 30 minutes after which the bottle containing the buffer was stoppered.

Inhibition of complement-mediated lysis of sensitised sheep erythrocytes was measured using a standard haemolytic assay using a v-bottom microtitre plate format as follows, essentially as described by Weisman *et al* (1990) Science 249 146-151.
 15 50 ul of a range of concentrations of inhibitor diluted in Hepes buffer were incubated with 50 ul of the 1/125. 100 ul of prewarmed sensitised sheep erythrocytes were added and samples incubated for 1 hour at 37°C in a final reaction volume of 200 ul. Samples were spun at 300g at 4°C for 15 minutes before transferring 150 ul of supernatant to flat bottom microtitre plates and determining the absorption at 410
 20 nm, which reflects the amount of lysis in each test solution. Maximum lysis was determined by incubating serum with erythrocytes in the absence of any inhibitor (E+S) from which the proportion of background lysis had been subtracted (determined by incubating erythrocytes with buffer (E). The background lysis by inhibitor was assessed by incubating inhibitor with erythrocytes (E+I) and then
 25 subtracting that from test samples (E+I+S). Inhibition was expressed as a fraction of the total cell lysis such that IH50 represents the concentration of inhibitor required to give 50% inhibition of lysis.

Maximum Lysis: $A_{max} = (E+S) - (E)$
 30 Lysis in presence of inhibitor: $A_o = (E+I+S) - (E+I)$
 Amount of inhibition: $IH = \frac{A_{max} - A_o}{A_{max}}$

Results

35 **E1** The peptides from each fraction were resuspended in 0.1 M Hepes pH 7.4/0.15 M NaCl buffer which had been made under N₂ to remove oxygen and limit the amount of oxidation to cyclic peptide. The peptides were assayed directly for anti-complement (anti-haemolytic) activity and the results are given below in Table 1.

Peptide	Peak 1 % Linear	Peak 2 % Circular	IH50 uM	
			Assay 1	Assay 2
E1 fraction A	6	61	200	160
E1 fraction B	15	61	600	
E1 fraction C	36	50	100	
E1 fraction D	49	35	75	90
E1 fraction E	72	8	40	

From the data it can be seen that this peptide demonstrates anti-haemolytic activity where increasing potency is correlated with an increase in the proportion of linear peptide (E1a). In forming the cyclic peptide (E1b), a disulphide is formed between two residues that are not normally paired in the native SCR which may constrain the peptide into an unfavorable structure.

E2 The peptide was assayed using buffer kept under N₂ as described above.
Three separate assays were carried out and the results gave a mean IH50 of ~670 uM.

E3 From SDS-PAGE the Mr of the conjugated peptide was estimated as ~ 8000 Da. The IH50 of the MAP peptide alone was approx. 2000 uM and for unconjugated E2 approx 600 uM. Conjugate E3 gave an IH50 of approximately 13 uM indicating a 46 fold improvement in the activity by multimerising the sites.

E4 The peptide was resuspended in 0.1 M Hepes pH 7.4/0.15 M NaCl buffer which had been made under N₂ to remove oxygen and limit the amount of oxidation to cyclic peptide. The peptide was found to have an IH50 of approximately 300 uM.

E5 The peptide was resuspended in 0.1M Hepes pH 7.4/0.15M NaCl. Activity of the peptide was determined as approximately 80 uM.